



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 233 075 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
21.08.2002 Bulletin 2002/34

(51) Int Cl.7: **C12Q 1/68**

(21) Application number: **02251007.7**

(22) Date of filing: **14.02.2002**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **15.02.2001 US 269059 P**

(71) Applicants:
• **WHITEHEAD INSTITUTE FOR BIOMEDICAL
RESEARCH**
Cambridge, MA 02142 (US)
• **THE GENERAL HOSPITAL CORPORATION**
Boston, MA 02114 (US)
• **JOHNS HOPKINS UNIVERSITY**
Baltimore, MD 21205 (US)

(72) Inventors:
• **Sklar, Pamela**
Brookline, Massachusetts 02446 (US)
• **Lander, Eric S.**
Cambridge, Massachusetts 02139 (US)
• **Depaulo, Raymond J., Jr.**
Baltimore, Massachusetts 21204-6526 (US)
• **McInnis, Melvin G.**
Timonium, Maryland 21093 (US)

(74) Representative: **Kirkham, Nicholas Andrew et al**
Graham Watt & Co.
St. Botolph's House
7-9 St. Botolph's Road
Sevenoaks Kent TN13 3AJ (GB)

(54) **BDNF polymorphism and association with bipolar disorder**

(57) Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and

pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

EP 1 233 075 A2

Description

[0001] Modern psychiatry typically subdivides mood disorders into bipolar disorders (episodes of mania or both mania and depression) and unipolar depressive disorder (episodes of depression). Symptoms of mania include expansive, elevated or irritable mood, inflated self-esteem, grandiosity, decreased need for sleep, increased talkativeness, racing thoughts, distractibility, increased goal-directed activity, and excessive involvement in pleasurable activities with a high potential for painful consequences. Depressive symptoms include depressed mood, diminished interest or pleasure in activities, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of energy, feelings of worthlessness, excessive guilt, inability to concentrate or act decisively, and recurrent thoughts of death or suicide. Several mental disorders have been proposed as alternate expressions of a bipolar genotype, including variants of schizoaffective disorder, recurrent unipolar depression and hypomania (bipolar II disorder).

[0002] Neuropsychiatric disorders, such as schizophrenia, attention deficit disorders, schizoaffective disorders, bipolar disorders and unipolar disorders, differ from neurological disorders in that anatomical or biochemical pathologies are readily detectable for the latter but not the former. Largely as a result of this difference, drugs which have been used to treat individuals with neuropsychiatric disorders, including lithium salts, valproic acid and carbamazepine, have not been predictably effective in treatment regimens across a variety of patients. Treatment regimens are further complicated by the fact that clinical diagnosis currently relies on clinical observation and subjective reports. Identification of the anatomical or biochemical defects which result in neuropsychiatric disorders is needed in order to effectively distinguish between the disorders and to allow the design and administration of effective therapeutics for these disorders.

[0003] As described herein, polymorphisms in the gene for brain-derived neurotrophic factor (BDNF) have been discovered, and at least one of the polymorphisms is correlated with incidence of neuropsychiatric disorders (e.g., bipolar disorder). A polymorphism at nucleotide position 31 in human brain-derived neurotrophic factor (as numbered in SEQ ID NO: 1, GenBank Accession No: M61181) has been discovered in which the reference "T" (thymine) is changed to "A" (adenine).

[0004] Furthermore, a single nucleotide polymorphism has been discovered within the nucleotide sequence encoding the 128 amino acid prepro portion of the BDNF gene product which is correlated with reduced incidence of bipolar disorder in a sample population assessed as described herein. In one embodiment, a single nucleotide polymorphism from "G" to "A" at nucleotide position 858 (as numbered in SEQ ID NO: 1), resulting in an amino acid change from valine to methionine at amino acid position -63 (relative to the start of the mature protein), is correlated with a reduced incidence of bipolar disorder in the sample population assessed as described herein. That is, it has been determined that there is a variation from random (i.e., that which would be expected by chance) in the transmission of the reference "G" (guanine) and variant "A" (adenine) at position 858 from a parent who is heterozygous for the BDNF alleles to an offspring diagnosed with bipolar disorder. It appears that this variant allele of the SNP in the prepro region of BDNF may contribute to protection or reduction in symptomology with respect to bipolar disorder. Alternatively, this particular polymorphism may be one of a group of two or more polymorphisms in the BDNF gene which contributes to the presence, absence or severity of the neuropsychiatric disorder, e.g., bipolar disorder.

[0005] The invention relates to methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders. The invention relates to novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders. The invention further relates to kits for use in diagnosing neuropsychiatric disorders. In a preferred embodiment, the neuropsychiatric disorder is bipolar disorder.

[0006] In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have a neuropsychiatric disorder (or aiding in the diagnosis of a neuropsychiatric disorder), e.g., bipolar disorder, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at nucleotide position 31 of the BDNF gene, as numbered in SEQ ID NO: 1. The presence of a "T" at position 31 indicates that the individual has a reduced likelihood of being diagnosed with a neuropsychiatric disorder than an individual having an "A" at that position. In a preferred embodiment, the neuropsychiatric disorder is bipolar disorder. In a particular embodiment, the individual is an individual at risk for development of bipolar disorder.

[0007] The method comprises obtaining a DNA sample from an individual to be assessed. The DNA sample comprises a polynucleotide sequence of the BDNF gene or portion thereof comprising position 31 of SEQ ID NO: 1. The nucleotide present at position 31 of said polynucleotide sequence is determined. The identity of the nucleotide at position 31 can be determined by nucleic acid detection methods well known in the art.

[0008] In another embodiment, the invention is drawn to a method of predicting the likelihood that an individual will have reduced symptomology associated with a neuropsychiatric disorder, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at nucleotide position 31 of the BDNF gene, as numbered in SEQ ID NO: 1. The presence of a "T" at position 31 indicates that the individual will have reduced symptomology associated with a neuropsychiatric disorder.

[0009] In another embodiment, the presence of an "A" at position 31, as numbered in SEQ ID NO: 1 indicates that a person will have an increased likelihood of being diagnosed with a neuropsychiatric disorder as compared with an individual having a "T" at the position.

[0010] The invention also relates to a kit for determining the genotype of a nucleotide corresponding to position 31 of SEQ ID NO: 1 in a polynucleotide sequence of interest. The kit comprises one or more nucleic acid probes, wherein one of said probes hybridizes to the polynucleotide sequence of interest, wherein the polynucleotide sequence of interest comprises the BDNF gene, its complement, or portion thereof and wherein the polynucleotide sequence of interest includes a nucleotide corresponding to position 31 of SEQ ID NO: 1. The kit can also comprise control nucleic acid samples representing the genotype of at least one of the group consisting of; an individual homozygous for an "A" at nucleotide position 31 of a BDNF gene, an individual homozygous for a "T" at nucleotide position 31 of a BDNF gene, and an individual heterozygous for said position, wherein position 31 corresponds to position 31 of SEQ ID NO: 1. The kits of the present invention are particularly suited for use in the method of the present invention, e.g., for predicting the likelihood that an individual will have or be diagnosed with a neuropsychiatric disorder, such as a bipolar disorder. In one embodiment, the kit comprises an SBE-FRET primer, wherein said primer hybridizes to a polynucleotide sequence comprising position 31 of SEQ ID NO: 1. In one embodiment, the polynucleotide sequence of interest is at least about 10 nucleotides in length. In another embodiment, the polynucleotide sequence is at least about 20 nucleotides in length.

[0011] In still another embodiment, the invention relates to a microarray, wherein the microarray has immobilized thereon a plurality of probes, wherein at least one of said probes is specific for the variant form of the single nucleotide polymorphism at position 31 of SEQ ID NO: 1. In another embodiment, at least one of the probes is specific for the reference form of the single nucleotide polymorphism at position 31 of SEQ ID NO: 1.

[0012] The invention also relates to a nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleic acid sequence which is at least 10 nucleotides in length. Said nucleic acid molecule includes a nucleotide corresponding to position 31 of SEQ ID NO: 1 or its complement wherein said nucleotide at position 31 of SEQ ID NO: 1 is an "A."

BRIEF DESCRIPTION OF THE DRAWINGS

[0013]

Figure 1 shows the polypeptide and polynucleotide sequence of BDNF, GenBank Accession M61181, SEQ ID NOs: 2 and 1, respectively.

Figure 2 shows the estimated relative risk of developing bipolar disorder based on data and analyses from the indicated groups of affected individuals and described in the Exemplification.

DETAILED DESCRIPTION OF THE INVENTION

[0014] The development and maintenance of the vertebrate nervous system depends, in part, on the physiological availability of neuronal survival proteins known as neurotrophic factors. Neurotrophic factors play a role in maintaining neurons and their differentiated phenotypes in the adult nervous system. Nerve growth factor (NGF) remains the best characterized neurotrophic factor. However, brain-derived neurotrophic factor (BDNF) has been cloned and shown to be homologous to NGF (Leibrock *et al.*, *Nature* 341:149-152 (1989); Hofer *et al.*, *EMBO J.* 9:2459-2464 (1990); Maisonpierre *et al.*, *Genomics* 10:558-568 (1991)). BDNF is initially synthesized as a 247 amino acid protein precursor that is subsequently cleaved to yield the mature protein. The mature form of BDNF essentially corresponds to the C-terminal half of its precursor and comprises 119 amino acids. In the developing rat, BDNF expression undergoes an increase from initially low levels, and in the adult rat central nervous system, BDNF is expressed at its highest level in the hippocampus. Expression of BDNF is detectable in adult tissues outside of the central nervous system only in heart, lung and skeletal muscle (Maisonpierre *et al.*, *Science*, 247:1446-1451 (1990); Hofer *et al.*, *EMBO J.*, 9: 2459-2464 (1990)).

[0015] As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A polymorphic locus may be as small as one base pair, in which case it is referred to as a single nucleotide polymorphism.

[0016] As described herein, polymorphisms in the gene for BDNF have been discovered. In one embodiment, a single polymorphism from T to A at nucleotide position 31 in the BDNF gene, as numbered in SEQ ID NO: 1, or at a nucleotide position corresponding thereto, has been discovered. It has also been discovered that one or more single nucleotide polymorphisms within the nucleotide sequence encoding the amino acid prepro portion of the BDNF gene product are correlated with a reduced incidence of bipolar disorder in the sample population assessed as described

herein. For example, a single polymorphism from G to A at nucleotide position 858 of SEQ ID NO: 1, resulting in an amino acid change from valine to methionine at amino acid position -63 (relative to the start of the mature protein), or at an amino acid position corresponding thereto, is correlated with a reduced incidence of bipolar disorder in the sample population assessed as described herein. This polymorphism resides within the amino acid precursor portion (the prepro portion) which is cleaved from the mature protein.

[0017] It appears that the variant allele at position 858 of BDNF may contribute to protection or reduction in symptomatology with respect to bipolar disorder. Alternatively, this particular polymorphism maybe one of group of two or more polymorphisms in the BDNF gene which contributes to the presence, absence or severity of the neuropsychiatric disorder, e.g., bipolar disorder. Therefore, because of the linkage disequilibrium, the transmission of at "T" at position 31 as numbered in SEQ ID NO: 1 is linked to transmission of "A" at position 858.

[0018] Variation at nucleotide 31 of SEQ ID NO: 1 is not in the coding region of the BDNF gene. Therefore, in terms of a phenotypic effect on the BDNF protein, variation at position 31 is silent. However, because blocks of the genome are consistently inherited together in a population (linkage disequilibrium), nearby linked SNPs (whether silent or not) may also reveal an association to an underlying causative SNP. As described herein, the presence of "T" at position 31 of the BDNF gene (as numbered in SEQ ID NO: 1) is in complete linkage disequilibrium with a variation at position 858. Position 858, in turn, shows a variation from random in the transmission of the reference "G" and variant "A" alleles from an individual parent who is heterozygous for the BDNF alleles to an offspring diagnosed with bipolar disorder. As described herein, the transmission of "A" at position 858 is associated with a reduced incidence of bipolar disorder. Therefore, because of the linkage disequilibrium, the transmission of "T" at position 31 as numbered in SEQ ID NO: 1 is linked to transmission of "A" at position 858.

[0019] Therefore, while not wishing to be bound by theory, variation at position 31 can aid in the diagnosis or prognosis of a neuropsychiatric disorder, such as bipolar disorder, due to linkage disequilibrium of position 31 with position 858. Determination of the identity of nucleotide 31 of the BDNF gene, as numbered in SEQ ID NO: 1, can be used to aid in the formulation of a diagnosis or prognosis of neuropsychiatric disease, such as bipolar disorder. Furthermore, as more allelic variations are discovered in genes involved in neuropsychiatric disorders, the ability to assess the genotype of an individual at one or more loci could facilitate the formulation of a diagnosis or prognosis of neuropsychiatric diseases, such as bipolar disorder.

[0020] Thus, the invention relates to a method for predicting the likelihood that an individual will have a neuropsychiatric disorder, or for aiding in the diagnosis of a neuropsychiatric disorder, e.g., bipolar disorder, or a greater likelihood of having reduced symptomatology associated with a neuropsychiatric disorder, e.g., bipolar disorder, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide genotype at nucleotide position 31 of the BDNF gene as numbered in SEQ ID NO: 1. In one embodiment, the nucleotide present at position 31 is identified. In a preferred embodiment, the neuropsychiatric disorder is bipolar disorder. In a particular embodiment, the individual is an individual at risk for development of bipolar disorder. In another embodiment the individual exhibits clinical symptomatology associated with bipolar disorder. In one embodiment, the individual has been clinically diagnosed as having bipolar disorder.

[0021] As used herein, "position 31" and "position 858" refer to nucleotide positions of the BDNF gene corresponding to positions 31 and 858, respectively of SEQ ID NO: 1, or the complement thereof. When referring to the complementary strand, it is understood that the complementary base of the indicated nucleotide of interest. The nucleotide positions of the polymorphisms can be referred to in a number of different ways. For convenience, the following table provides a cross-reference between two common numbering schemes: the numbering based on GenBank sequence M61181 (SEQ ID NO: 1), and numbering based on the starting codon of the prepro protein (where the first nucleotide in the starting ATG codon is "1" and for example, the nucleotide upstream of "1" is "-1".

TABLE I

Nucleotide Position of SEQ ID NO: 1	Nucleotide Position Relative to First Position of Starting ATG ¹
31	-633
858	196

1. Position 663 of SEQ ID NO: 1.

[0022] The genetic material to be assessed can be obtained from any nucleated cell from the individual. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from an organ in which the target nucleic acid is expressed. For example, cells from the central nervous system (such as cells of the hippocampus), neural crest-derived cells, skin, heart, lung and skeletal muscle are suitable sources for obtaining cDNA for the BDNF gene. Neural crest derived cells include,

for example, melanocytes and keratinocytes.

[0023] Many of the methods described herein require amplification of DNA from target samples. This can be accomplished by e.g., PCR. See generally *PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, CA, 1990); Mattila et al., *Nucleic Acids Res.* 19, 4967 (1991); Eckert et al., *PCR Methods and Applications* 1, 17(1991); *PCR* (eds. McPherson et al., IRL Press, Oxford); and U.S. Patent 4,683,202.

[0024] Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, *Genomics* 4, 560 (1989), Landegren et al., *Science* 241, 1077(1988), transcription amplification (Kwoh et al., *Proc. Natl. Acad. Sci. USA* 86, 1173 (1989)), and self-sustained sequence replication (Guatelli et al., *Proc. Nat. Acad. Sci. USA*, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

[0025] The nucleotide which occupies the polymorphic site of interest (e.g., nucleotide position 31 in BDNF as numbered in SEQ ID NO: 1) can be identified by a variety of methods, such as Southern analysis of genomic DNA; direct mutation analysis by restriction enzyme digestion; Northern analysis of RNA; denaturing high pressure liquid chromatography (DHPLC); gene isolation and sequencing; hybridization of an allele-specific oligonucleotide with amplified gene products; single base extension (SBE); or analysis of the BDNF protein. In a preferred embodiment, determination of the allelic form of BDNF is carried out using SBE-FRET methods as described in the examples, or using chip-based oligonucleotide arrays. A sampling of suitable procedures are discussed below in turn.

1. Allele-Specific Probes

[0026] The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki et al., *Nature* 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Hybridizations are usually performed under stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25°C. For example, conditions of 5X SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30°C, or equivalent conditions, are suitable for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

[0027] Some probes are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

[0028] Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence. Allele specific probes can comprise DNA, peptide nucleic acid (PNA) and RNA, or combinations thereof.

2. Tiling Arrays

[0029] The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles, except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

3. Allele-Specific Primers

[0030] An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, *Nucleic Acid Res.* 17,

2427-244 (89), This primer is used in conjunction with a second primer which hybridizes at a distal site. Amplification proceeds using the two primers, resulting in a detectable product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3'-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

4. Direct-Sequencing

[0031] The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam Gilbert method (see Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd Ed., CSHP, New York 1989); Zyskind *et al.*, *Recombinant DNA Laboratory Manual*, (Acad. Press, 1988)).

5. Denaturing Gradient Gel Electrophoresis

[0032] Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., *PCR Technology, Principles and Applications for DNA Amplification*, (W.H. Freeman and Co, New York, 1992), Chapter 7.

6. Single-Strand Conformation Polymorphism Analysis

[0033] Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita *et al.*, *Proc. Nat. Acad. Sci.* 86, 2766-2770(1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

7. Single-Base Extension

[0034] An alternative method for identifying and analyzing polymorphisms is based on single-base extension (SBE) of a fluorescently-labeled primer coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer. Typically, the method, such as that described by Chen *et al.*, (*PNAS* 94: 10756-61 (1997), incorporated herein by reference) uses a locus-specific oligonucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxynucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

[0035] The polymorphisms of the invention may contribute to the protection of an individual against bipolar disorder in different ways. The polymorphisms may contribute to phenotype by affecting protein structure. By altering amino acid sequence, the polymorphism may alter the function of the encoded protein. The polymorphisms may exert phenotypic effects indirectly via influence on replication, transcription, and translation. For example, the substitution of a methionine for a valine in the prepro portion of the BDNF gene product may create an alternative translation start site which alters the length of the gene product and the prepro portion itself. Alteration of the length of the gene product may affect cleavage of the mature protein either positively or negatively. Alternatively, the presence of the variant amino acid may alter the properties of the gene product so as to alter cleavage of the gene product. More than one phenotypic trait may be affected. For example, other neuropsychiatric disorders which are believed to be alternate expressions of a bipolar genotype, including variants of schizoaffective disorder, recurrent unipolar depression and hypomania (bipolar II disorder), may also be affected by the BDNF polymorphisms described herein. Additionally, the described polymorphisms may predispose an individual to a distinct mutation that is causally related to a certain phenotype, such as susceptibility or resistance to bipolar disorder. The discovery of the polymorphisms and correlation with bipolar disorder facilitates biochemical analysis of the variant and the development of assays to characterize the variant and to screen for pharmaceuticals that interact directly with one or another form of the protein.

[0036] Alternatively, the polymorphisms may be one of a group of two or more polymorphisms in the BDNF gene which contributes to the presence, absence or severity of the neuropsychiatric disorder, e.g., bipolar disorder. An assessment of other polymorphisms within the BDNF gene can be undertaken, and the separate and combined effects of these polymorphisms on the neuropsychiatric disorder phenotype can be assessed.

[0037] Correlation between a particular phenotype, e.g., the bipolar phenotype, and the presence or absence of a particular allele is performed for a population of individuals who have been tested for the presence or absence of the phenotype. Correlation can be performed by standard statistical methods such as a Chi-squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, as described herein, it has been found that the presence of the BDNF variant allele, having an A at polymorphic site 858 (as numbered in SEQ ID NO: 1), correlates negatively with bipolar disorder with a p value of $p=0.004$ by Chi-squared test.

[0038] This correlation can be exploited in several ways. In the case of a strong correlation between a particular polymorphic form, e.g., the reference allele for BDNF, and a disease for which treatment is available, e.g., bipolar disorder, detection of the polymorphic form in an individual may justify immediate administration of treatment, or at least the institution of regular monitoring of the individual. Detection of a polymorphic form correlated with a disorder in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo *in vitro* fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic form and a particular disorder, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the individual can be motivated to begin simple life-style changes (e.g., therapy or counseling) that can be accomplished at little cost to the individual but confer potential benefits in reducing the risk of conditions to which the individual may have increased susceptibility by virtue of the particular allele. Furthermore, identification of a polymorphic form correlated with enhanced receptiveness to one of several treatment regimes for a disorder indicates that this treatment regime should be followed for the individual in question.

[0039] Furthermore, it may be possible to identify a physical linkage between a genetic locus associated with a trait of interest (e.g., bipolar disorder) and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 83, 7353-7357 (1986); Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84, 2363-2367 (1987); Donis-Keller *et al.*, *Cell* 51, 319-337 (1987); Lander *et al.*, *Genetics* 121, 185-199 (1989). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, *Med. J. Australia* 159, 170-174 (1993); Collins, *Nature Genetics* 1, 3-6 (1992).

[0040] Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic trait and for a set of polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem *et al.*, *Science* 245, 1073-1080 (1989); Monaco *et al.*, *Nature* 316, 842 (1985); Yamoka *et al.*, *Neurology* 40, 222-226 (1990); Rossiter *et al.*, *FASEB Journal* 5, 21-27 (1991).

[0041] Linkage is analyzed by calculation of LOD (log of the odds) values. A LOD value is the relative likelihood of obtaining observed segregation data for a marker and a genetic locus when the two are located at a recombination fraction 0, versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, *Genetics in Medicine* (5th ed, W.B. Saunders Company, Philadelphia, 1991); Strachan, "Mapping the human genome" in *The Human Genome* (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions (θ), ranging from $\theta = 0.0$ (coincident loci) to $\theta = 0.50$ (unlinked). Thus, the likelihood at a given value of θ is: probability of data if loci linked at θ to probability of data if loci unlinked. The computed likelihoods are usually expressed as the \log_{10} of this ratio (i.e., a LOD score). For example, a LOD score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of LOD scores for differing values of θ (e.g., LIPED, MLINK (Lathrop, *Proc. Nat. Acad. Sci. (USA)* 81, 3443-3446 (1984)). For any particular LOD score, a recombination fraction may be determined from mathematical tables. See Smith *et al.*, *Mathematical tables for research workers in human genetics* (Churchill, London, 1961); Smith, *Ann. Hum. Genet.* 32, 127-150 (1968). The value of θ at which the LOD score is the highest is considered to be the best estimate of the recombination fraction.

[0042] Positive LOD score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of θ) than the possibility that the two loci are unlinked. By convention, a combined LOD score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative LOD score of -2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

[0043] The invention also encompasses kits for detecting the presence of proteins or nucleic acid molecules of the invention in a biological sample. For example, the kit can comprise a compound or agent (e.g., one or more nucleic acid probes) capable of detecting protein or mRNA (or cDNA produced from the mRNA) in a biological sample or means for determining the identity of a particular nucleotide or amino acid of the BDNF gene or protein, respectively. For example, in one embodiment, the kit comprises a means for determining the identity of nucleotide 31 of BDNF gene as numbered in SEQ ID NO: 1. In another embodiment, the compound or agent, such as oligonucleotide(s) or antibody(ies) is labeled. In still another embodiment, the kit includes fluorescently labeled dideoxynucleotides. The kit can also comprise control samples for use as standards, representing individuals homozygous for the reference or variant nucleotide in the case of analyzing nucleic acid, or the reference or variant amino acid in the case of analyzing proteins, or representing a heterozygous individual. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect protein or nucleic acid.

[0044] The invention further pertains to compositions, e.g., vectors, comprising a nucleotide sequence encoding variant BDNF gene. In one embodiment, the gene comprises BDNF sequences including position 31 of SEQ ID NO: 1.

[0045] For example, the BDNF gene or variants thereof can be expressed in an expression vector in which a variant gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

[0046] The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, *supra*. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as *E. coli*, yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, e.g., mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like.

[0047] It is also contemplated that cells can be engineered to express the BDNF allele of the invention by gene therapy methods. For example, DNA encoding the BDNF gene product, or an active fragment or derivative thereof, can be introduced into an expression vector, such as a viral vector, and the vector can be introduced into appropriate cells in an animal. In such a method, the cell population can be engineered to inducibly or constitutively express active BDNF gene product. In a preferred embodiment, the vector is delivered to the bone marrow, for example as described in Corey *et al.* (*Science* 244:1275-1281 (1989)).

[0048] The invention further provides transgenic nonhuman animals capable of expressing an exogenous BDNF gene and/or having one or both alleles of an endogenous BDNF gene inactivated. Expression of an exogenous gene is usually achieved by operably linking the gene to a promoter and optionally an enhancer, and microinjecting the construct into a zygote. See Hogan *et al.*, "Manipulating the Mouse Embryo, A Laboratory Manual," Cold Spring Harbor Laboratory. Inactivation of endogenous genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive selection marker. See Capecchi, *Science* 244, 1288-1292 (1989). The transgene is then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

[0049] The invention further relates to an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes wherein at least one of said probes is specific for the nucleotide at position 31 of SEQ ID NO: 1. In one embodiment, the invention relates to an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes wherein at least one of said probes is specific for the variant nucleotide at position 31 of SEQ ID NO: 1. In another embodiment, the invention relates to an oligonucleotide microarray having immobilized thereon a plurality of oligonucleotide probes wherein at least one of said probes is specific for the reference nucleotide at position 31 of SEQ ID NO: 1. The nucleic acid sequence surrounding the position 31 of SEQ ID NO: 1 can be used to design suitable oligonucleotide probes, and the preparation of such oligonucleotide microarrays is well known in the art.

[0050] The invention will be further illustrated by the following non-limiting examples. The teachings of the references cited herein are incorporated herein by reference in their entirety.

EXAMPLES

Sample Population

[0051] A sample population of 150 trios was initially assessed by genotyping methods for heterozygosity with

respect to the BDNF reference and variant alleles as described herein. A trio included two parents and an offspring diagnosed as having bipolar disorder according to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. Of the 150 trios assessed, 98 of these trios had at least one parent who was heterozygous for the BDNF reference and variant alleles; these 98 trios were selected for further study, as the heterozygosity of the parent allowed a determination of which allele the parent transmitted to the bipolar offspring. The bipolar offspring in the trios were assessed by genotyping methods to determine which BDNF allele had been transmitted to them by the heterozygous parent. In instances where two parents had two offspring diagnosed with bipolar disorder, each trio (i.e., two parents and one offspring) was considered individually.

SBE-FRET Protocol

[0052] The genotyping method used for these studies was based on single-base extension (SBE) and fluorescence resonance energy transfer (FRET). A locus-specific primer (FRET primer; 5'-GGCTGACACTTTTGAACAC (SEQ ID NO: 3) was ordered 5' labeled with FAM. The primer was designed so that the 3' end hybridized immediately adjacent to the polymorphic site of interest (e.g., nucleotide 858), such that a single-base extension of the primer would result in the addition of a nucleotide complementary to the template polymorphic site of interest. Locus specific primer for other positions of interest, such as position 31 of SEQ ID NO: 1, can be readily designed and labeled with FAM using methods well known in the art. The locus of interest was amplified and single base extension of the FRET primer was performed with fluorescently labeled ddNTPs in dye-terminator sequencing fashion, except that no deoxyribonucleotides are present. PCR primers were:

Forward PCR primer 5'-TGTA AACGACGGCCAGTCTTGACATCA
T'TGGCTGACACT (SEQ ID NO: 4); and

Reverse PCR primer 5'-TAATACGACTCACTATAGGGGTACAAGT
C'TGCGTCCTTATTGTTT (SEQ ID NO: 5).

[0053] The ddNTP corresponding to the variant base (A) was labeled with TAMRA, and the reference base (G) was labeled with ROX. Depending on the genotype of the individual, the FRET primer was extended with a ROX-labeled or TAMRA-labeled ddNTP. Upon incorporation of either ROX- or TAMRA-labeled ddNTPs, energy transfer occurs between the donor dye (FAM on FRET primer) and the acceptor dye (the ROX- or TAMRA-labeled ddNTP). An increase in the fluorescence intensity of one (for a homozygote) or both (for a heterozygote) of the acceptor dyes was used to infer the genotype of an individual.

[0054] Summary of experimental procedures used in the above-described analysis.

I Amplify locus of interest

II Clean-up of PCR products with shrimp alkaline phosphatase (SAP) and Exonuclease 1 (EXO)

III Single-base extension/fluorescence detection in ABI7700

I Amplification of locus of interest - for 96-well plate

[0055]

TABLE II:

PCR MIX		
	Each Reaction (μL)	For 96-well plate (μL)
10 mM dNTP	0.05	5.2
10X PCRII buffer	2.0	208
25 mM MgCl ₂	1.2	125
20 μM PCR primer F	0.25	26

EP 1 233 075 A2

TABLE II: (continued)

PCR MIX		
	Each Reaction (μL)	For 96-well plate (μL)
20 μM PCR primer R	0.25	26
ddH ₂ O	11.05	1149
5 U/μL Amplitaq-gold	<u>0.2</u>	20.8
	15	

[0056] Fifteen microliters of the PCR mix were added to a 96-well MJ plate. Five microliters of genomic DNA (5 ng/μL) were added to the aliquoted PCR mix. (5 μL of 1 ng/μL is often adequate).

[0057] The plate was sealed with MJ plate-seal 'A'.

[0058] PCK was conducted using the following program:

96°C x 10 minutes

96°C x 30 seconds, 50°C x 1 minute, 72°C x 1 minute for 35 cycles

72°C x 10 minutes followed by a hold at 4°C

II PCR product clean-up

[0059]

TABLE III:

SAP/EXO MIX		
	Each reaction (μL)	For 96-well plate (μL)
Shrimp alkaline phosphatase (1U/μL)	1.0	104
Exonuclease 1 (10 U/μL)	0.05	5.2
10X SAP buffer	1.0	104
ddH ₂ O	<u>2.95</u>	306.8
	5.0	

[0060] Five microliters of SAP/EXO mix were added to a clean MJ plate. Five microliters of the PCR product were added directly to the aliquoted SAP/EXP mix. The PCR plates were spun down and sealed with Microseal A film. The mixture was incubated at 37°C for 45 minutes and then at 96°C for 15 minutes.

III Single-base extension/fluorescence detection in ABI7700

(The reactions were carried out in the same MJ plate used for SAP/EXO step, capped with 8-strip MicroAmp optical caps)

[0061] The ddNTPs that should be incorporated in the genotyping reaction were selected. In this experiment, TAMRA was used to identify the variant base and ROX for the reference base, although other possibilities exist.

TABLE IV:

SBE-FRET MIX		
	Each reaction (μL)	For 96-well plate (μL)
FAM primer (100 uM)	0.02	2.08
ROX ddNTP (100 um)	0.02	2.08
TAMRA ddNTP (100 um)	0.02	2.08
Thermoseq. Buffer (10x)	2.0	208

EP 1 233 075 A2

TABLE IV: (continued)

SBE-FRET MIX		
	Each reaction (μL)	For 96-well plate (μL)
ddH ₂ O	7.9	821.6
Thermosequenase (32 U/μL)	0.016	1.7
	10.0	

- Ten microliters of SBE-FRET mix were added to the MJ plates containing 10 μL SAP/Exo treated PCR products.
- The plates were tapped on bench to mix, they can also be spun briefly if necessary.
- The wells were capped with optical caps. The capped wells can be rolled with roller if necessary.
- The plates were placed in a thermocycling detector apparatus (AB17700).
- The plates were incubated for 6 cycles of (for a 20 μL reaction) as follows:

96°C x 15 seconds
50°C x 30 seconds
60°C x 30 seconds

[0062] Data were collected in the 60°C stage using detection settings suitable for measuring TAMRA and ROX fluorescence.

[0063] Data were analyzed by plotting ROX fluorescence versus TAMRA fluorescence and comparing the values between samples, control samples containing no template and samples of known genotype. Typically, homozygous reference controls have little or no TAMRA fluorescence, homozygous variant controls have little or no ROX fluorescence and heterozygous controls have similar TAMRA and ROX fluorescence.

Results

[0064] Data from the work described herein has shown that there is a variation from random (i.e., that which would be expected by chance) in the transmission at position 858 of SEQ ID NO: 1 of the reference (G) and variant (A) alleles from an individual parent who is heterozygous for the BDNF alleles to an offspring diagnosed with bipolar disorder.

[0065] The data demonstrated that the variant allele (A) is transmitted less frequently (34 of 98 times) to the bipolar offspring than would be expected by chance, while the reference allele (G) is transmitted more frequently (64 of 98 times) than would be expected by chance ($p = 0.004$). In the general population (in which about 0.8 percent of the individuals are diagnosed with bipolar disorder), the variant (A) allele occurs with a frequency of 15 percent, while the reference allele occurs with a frequency of 85 percent. In the sample population assessed as described herein, in which all of the individuals are diagnosed with bipolar disorder, the variant allele occurs with a frequency of 7 percent. Thus, it appears that the variant allele may contribute to protection or reduction in symptomology with respect to bipolar disorder.

[0066] Figure 2 and Table V show data obtained from additional human samples.

TABLE V

Samples	Trans	Untrans.	p val	# trans	relative risk	95% CF	# trios
Hopkins	55	29	0.0023	84	1.90	1.25-3.0	127
U01 + NIMH	50	42	0.2021	92	1.19	0.83-1.8	155
British	38	32	0.2366	70	1.19	0.77-1.8	145
all repl.	88	74	0.1357	162	1.19	0.91-1.8	300
all BP	143	103	0.0054	246	1.39	1.1-1.8	427

[0067] "Hopkins" refers to a to a group of patients with bipolar disorder obtained in collaboration with Johns Hopkins. "U01 and NIMH" refer to a group of 155 trios, some of which are from Johns Hopkins and some of which are from the Genetics Initiative at the NIMH. "British" refers to 145 trios from 5 collaborators in England.

[0068] In Table V, "Trans" is the number of times the allele in question (at position 858, in this case the reference allele) was transmitted from a heterozygous parents to a bipolar child. "Untrans" is the number of times the other

EP 1 233 075 A2

(variant) allele was passed from the heterozygous parent to the bipolar child. The number of trios used is shown in the column labeled "# trios" and is the number of trios for which genotypes were available. Not all of the parents were considered to be "informative". To be included in the analysis, the parent in question had to be a heterozygote.

[0069] The relative risk (estimated relative risk on Figure 2) is defined as the transmission ratio in trios (i.e. # transmitted alleles/# untransmitted alleles). Under a multiplicative disease model, this is an estimator of genotypic relative risk. The confidence interval was calculated using a binomial distribution.

[0070] The combination of "T" at position 31 and "A" at position 858 was tested and found to be in nearly complete linkage disequilibrium in both the Hopkins and the NIMH datasets.

[0071] While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

SEQUENCE LISTING

<110> Sklar, Pamela
 Lander, Eric S.
 DePaulo, J. Raymond, Jr.
 McInnis, Melvin G.

<120> BDNF Polymorphism and Association with
 Bipolar Disorder

<130>

<150> US 60/269,059

<151> 2001-02-15

<160> 5

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1685

<212> DNA

<213> Homo sapiens

<400> 1

tgtaaaacag	gatgggtcaa	tgaattatc	tttcttctt	ctataataga	gtatctctgt	60
gggaagagga	aaaaaaaaagt	caatttraaag	gtctcttata	gttccccaac	tgctgtttta	120
ttgtgctatt	catgcctaga	catcacatag	ctagaaaaggc	ccatcagacc	cctcaggcca	180
ctgctgttcc	tgtcacacat	tcttgcaagg	gacctgttg	ctaacttgaa	aaaaattact	240
attaattaca	cttgcaagt	ttgcttagta	acatttatga	ttttgtgttt	ctcgtgacag	300
catgagcaga	gatcattaaa	aattaaactt	acaaagctgc	ttaaagtggga	agaaggagaa	360
cttgaagcca	caatttttgc	acttgcttag	aagccatcta	atctcaggtt	atatgctaga	420
tcttgggggc	aaacactgca	tgtctctggt	ttatattaaa	ccacatacng	cacactactg	480
ccactgattt	gtgtctgtgt	cagctggagt	tatcaccagg	acataaaaaa	accttgacco	540
tgcagaatgg	cctggaatac	aatcagaggg	ccacatggca	tcccgggtga	agaaagccct	600
aaccagtttt	ctgtcttgtt	tctgctttct	ccctacagtt	ccaccaggtg	agaagagtga	660
tgaccatcct	tttctttact	atgggttatt	catactttgg	ttgcatgaag	gctgccccca	720
tgaagaaga	aaacatccga	ggacaagggt	gcttggccct	cccaggtgtg	cggacccatg	780
ggactctgga	gagcgtgaat	gggcccagg	caggttcaag	aggcttgaca	tcatlggctg	840
acacttttga	acacatgata	gaagagctgt	tggatgagga	ccagaaaagt	cggcccaatg	900
aagaaaacaa	taaggacgca	gacttgtaca	cgtccagggt	gatgctcagt	agtcaagtgc	960
ctttggagcc	tctctctctc	tttctgtctg	aggaatacaa	aaattacctt	gatgctgcaa	1020
acatgtccat	gagggtccgg	cggcactctg	accctgccc	ccgaggggag	ctgagcgtgt	1080
gtgacagtat	tagtgagtg	gtaacggcgg	cagacaaaaa	gactgcagtg	gacatgtcgg	1140
gcgggacggt	cacagtcctt	gaaaagggtc	ctgtatcaaa	aggccaactg	aagcaatact	1200
tctacgagac	caagtgcatt	cccatgggtt	acacaaaaga	aggctgcagg	ggcatagaca	1260
aaaggcattg	gaactcccag	tgccgaacta	cccagtcgta	cgtgcggggc	cttaccatgg	1320
atagcaaaaa	gagaattggc	tggcgattca	taaggataga	cacttcttgc	gtatgtacat	1380
tgaccattaa	aaggggaaga	tagtggattt	atgttgtata	gattagatta	tattgagaca	1440
aaaatttatc	atttgtatat	atacataaca	gggttaaatta	ttcagttaag	aaaaaaaaaa	1500
ttttatgaac	tgcattgtata	aatgaagttt	atacagtaca	gtgggtctac	aatctattta	1560
ttggacatgt	ccatgaccag	aagggaacaa	gtcatttgcg	cacaacttaa	aaagtctgca	1620
ttacattcct	tgataatggt	gtgggtttgt	gccgttgcca	agaactgaaa	acataaaaaa	1680
ttaaa						1685

<210> 2

<211> 247

<212> PRT

<213> Homo sapiens

<400> 2
 Met Thr Ile Leu Phe Leu Thr Met Val Ile Ser Tyr Phe Gly Cys Met
 1 5 10 15
 5 Lys Ala Ala Pro Met Lys Glu Ala Asn Ile Arg Gly Gln Gly Gly Leu
 20 25 30
 Ala Tyr Pro Gly Val Arg Thr His Gly Thr Leu Glu Ser Val Asn Gly
 35 40 45
 10 Pro Lys Ala Gly Ser Arg Gly Leu Thr Ser Leu Ala Asp Thr Phe Glu
 50 55 60
 His Met Ile Glu Glu Leu Leu Asp Glu Asp Gln Lys Val Arg Pro Asn
 65 70 75 80
 Glu Glu Asn Asn Lys Asp Ala Asp Leu Tyr Thr Ser Arg Val Met Leu
 85 90 95
 15 Ser Ser Gln Val Pro Leu Glu Pro Pro Leu Leu Phe Leu Leu Glu Glu
 100 105 110
 Tyr Lys Asn Tyr Leu Asp Ala Ala Asn Met Ser Met Arg Val Arg Arg
 115 120 125
 His Ser Asp Pro Ala Arg Arg Gly Glu Leu Ser Val Cys Asp Ser Ile
 130 135 140
 20 Ser Glu Trp Val Thr Ala Ala Asp Lys Lys Thr Ala Val Asp Met Ser
 145 150 155 160
 Gly Gly Thr Val Thr Val Leu Glu Lys Val Pro Val Ser Lys Gly Gln
 165 170 175
 Leu Lys Gln Tyr Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr
 180 185 190
 25 Lys Glu Gly Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys
 195 200 205
 Arg Thr Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys
 210 215 220
 Arg Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr
 225 230 235 240
 30 Leu Thr Ile Lys Arg Gly Arg
 245

<210> 3
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> FRET Primer

40 <400> 3
 ggctgacact ttcgaacac 19

45 <210> 4
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

50 <400> 4
 tgtaaaacga cggccagtct tgacatcatt ggetgacact 40

55 <210> 5
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Primer

<400> 5

taatacgact cactataggg gtacaagtct gcgtccttat tgttt

45

Claims

1. A kit for determining the genotype of an individual at a nucleotide corresponding to position 31 of a BDNF gene in a polynucleotide sequence of interest comprising:

a) one or more nucleic acid probes, wherein at least one of said probes hybridizes to the polynucleotide sequence, wherein the polynucleotide sequence comprises the BDNF gene, its complement, or portion thereof, and wherein the polynucleotide sequence includes a nucleotide corresponding to position 31 of SEQ ID NO 1; and

b) control nucleic acid samples representing the gene type of at least one of the group consisting of: an individual homozygous for a "A" at nucleotide position 31 of the BDNF gene, an individual homozygous for a "T" at nucleotide position 31 of the BDNF gene, and a individual heterozygous for said position, wherein position 31 corresponds to position 31 of SEQ ID NO 1.

2. A kit of claim 1, wherein:

a) the nucleic acid probe is an SBE-FRET primer, and wherein the SBE-FRET primer hybridizes to the polynucleotide sequence such that the nucleotide corresponding to position 31 of SEQ ID NO 1 is immediately adjacent to the 3' terminus of the SBE-FRET primer, and optionally wherein the SBE-FRET primer comprises SEQ ID NO 3; and/or further comprising fluorescently labeled didexynucleotides; and/or

b) the control nucleic acid samples comprise amplified DNA; and optionally wherein the control samples are amplified using primers comprising SEQ ID NO 4 and SEQ ID NO 5; and/or

c) the polynucleotide sequence of interest comprises a nucleic acid sequence of at least 10 nucleotides in length, wherein said nucleic acid of interest comprises a BDNF gene or portion thereof, including position 31 of SEQ ID NO 1; and optionally wherein the polynucleotide sequence of interest is at least 20 nucleotides in length.

3. A nucleic acid molecule comprising a nucleic acid sequence which is at least 10 nucleotides in length, wherein said nucleic acid molecule includes a nucleotide corresponding to position 31 of SEQ ID NO 1 or its complement, wherein said nucleotide at position 31 of SEQ ID NO 1 is an "A".

4. A nucleic acid molecule according to claim 3, wherein said nucleic acid sequence is at least 20 nucleotides in length.

5. A method for predicting the likelihood that an individual will be diagnosed with a bipolar disorder, comprising the steps of:

a) providing a DNA sample obtained from an individual to be assessed; and

b) determining the nucleotide present at nucleotide position 31 of brain-derived neurotrophic factor gene, as numbered in SEQ ID NO 1,

wherein the presence of a "T" at position 31 indicates that the individual has a reduced likelihood of being diagnosed with a bipolar disorder as compared with an individual having an "A" at that position.

6. A method according to claim 5, wherein the individual is an individual at risk for development of a bipolar disorder.

7. A method for predicting the likelihood that an individual will be diagnosed with a bipolar disorder, comprising the steps of:

EP 1 233 075 A2

- a) providing a DNA sample obtained from an individual to be assessed; and
- b) determining the nucleotide present at nucleotide position 31 of brain-derived neurotrophic factor gene, as numbered in SEQ ID NO 1,

wherein the presence of an "A" at position 31 indicates that the individual has an increased likelihood of being diagnosed with a bipolar disorder as compared with an individual having a "T" at that position.

8. A method according to claim 7, wherein the individual:

- a) exhibits clinical symptoms of mania or mania and depression, or
- b) is an individual at risk for development of a bipolar disorder.

9. A method according to any one of claims 5 to 8, wherein the nucleotide at position 31 is determined by single-base extension using a primer capable of hybridizing to SEQ ID NO 1, its complement or portions thereof, such that a nucleotide corresponding to nucleotide 31 of SEQ ID NO 1 is immediately adjacent to the 3' terminus of said primer; and optionally wherein the primer comprises SEQ ID NO 3 or its complement, and/or the primer is immobilized on a solid support.

10. An oligonucleotide microarray having immobilized thereon a plurality of probes, wherein at least one of said probes is specific for either the variant form or the reference form of the single nucleotide polymorphism at position 31 of SEQ ID NO 1.

11. A compound for use in the treatment of bipolar disorders in an individual, wherein the individual has had determined the nucleotide present at nucleotide position 31 of brain-derived neurotrophic factor gene as numbered is SEQ ID NO 1, and the compound is selected based upon said determination.

MTILFLTMVISYFGCMKAAPMKEANIRGQGGLAYPGVTRTHGTLESVNGPKACSRQITTS
 LADTFEHMIEELLDEDDQKVRPNEENNKDADLYTSRVMLSSQVPLEPPLFLLEBYKNY
 LDAANMSMRVRRHSDPARRGELSVCDSEWVTAADKKTAVDMSGGTVTVIKVPVSK
 GQLKQYFYETKCNPMOYTKEGCRGIDKRHWNSQCRRTQSYVRALTMDSKKRIGWRPFR
 IDTSCVCTLTIKRGR

SEQ ID NO: 2

```

1  tgtaaaacag gatggctcaa tgaattatc tttcttcttt ctacaataga gtatctctgt
61  gggaagagga aaaaaaaagt caatttaaag gctccttata gttccccaac tgcctgtttta
121 ttgtgctatt catgcctaga catcacatag ctagaagggc ccatcagacc cctcaggcca
181 ctgctgttcc tgtcacacat tcccgcaaag gacctgttg ctaacttgaa aaaaatttct
241 attaatata cttgcagttg ttgcttagta acatttatga ttttggtgtt ctgctgacag
301 catgagcaga gatcatlaaa aattaaactt acaaagctgc taaagtgggn agnaggngn
361 cttgaagcca caatttttgc acttgctlag aagccatcta atctcagggt abatgctaga
421 tcttgggggc aaacactgca tgtctctggt ttatatataa ccacatacag cacactactg
481 aactgatttt gtgtctgggt cagctggagt ttatcaccaa gacataaaaa aactctgacc
541 ctgcagaatg gcctggaatt acaatcagat gggccacatg gcaccccggt gaaagaaagc
601 cctaaccagt tttctgtctt gttctctgct tctccctaca gtccaccag gtgagaagng
661 tgatgaccat ccttttccct actatggtta tttcatactt tgggttgcag aaggtctgcc
721 ccatgaaaga agcaaacatc cgaggacaag gtggcttggc ctaccagggt gtgctggacc
781 atgggactct ggagagcgtg aatgggcccc aggcagggtt naggaggctt acatcatagg
841 ctgacacttt cgaacacatg atagaagagc tgltygatga ggaccagaaa gtctggcccc
901 atgaagaaaa caataaggac gcagacttgt acacgtccag ggtgatgtct agtagtcaag
961 tgccttttga gcctcctctt ctctttctgc tggaggaata caaaaattac ctatgtgctg
1021 caaacatgtc catgaggggt cggcgccact ctgaccctgc ccgccgaggg gagctgagcg
1081 tgtgtgacag tattagttag tgggttaarg cggcagacaa aaagactgca gtggncatgt
1141 cgggcggggc ggtcacagtc cttgaaaagg tccctgtatc aaaaggccaa ctgaagcaat
1201 acttctacga gaccaagtgc aatcccatgg gttacacaaa agnaggctgc aggggcatag
1261 acaaaaaggca ttggaactcc cagtgccgaa ctaccagtc gtacgtgcgg gccctacca
1321 tggatagcaa aaagagaatt ggctggcgat tcataaggat agacacttct tgtgtatgta
1381 cattgaccat taaaagggga agatagtggg tttatgttgt atagattaga ttatattgag
1441 acaaaaatta tctatttgta tatatacata acagggttaa ttattcagtc aagaaaaaaa
1501 taatttttat aactgcatgt ataaatgaag ttatatacag acagtgggtc tacaatctat
1561 ttattggaca tgtccatgac cagaagggaa acagtcattt gcgcacaact taaaaagttc
1621 gcattacatt ccttgataat gttgtggttt gttgccgttg ccaagaactg aaaaacataa
1681 aagttaaa

```

SEQ ID NO: 1

FIG. 1




FIG. 2

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 233 075 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
08.01.2003 Bulletin 2003/02

(51) Int Cl.7: **C12Q 1/68**

(43) Date of publication A2:
21.08.2002 Bulletin 2002/34

(21) Application number: **02251007.7**

(22) Date of filing: **14.02.2002**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **15.02.2001 US 269059 P**

(71) Applicants:
• **WHITEHEAD INSTITUTE FOR BIOMEDICAL
RESEARCH**
Cambridge, MA 02142 (US)
• **THE GENERAL HOSPITAL CORPORATION**
Boston, MA 02114 (US)
• **JOHNS HOPKINS UNIVERSITY**
Baltimore, MD 21205 (US)

(72) Inventors:
• **Sklar, Pamela**
Brookline, Massachusetts 02446 (US)
• **Lander, Eric S.**
Cambridge, Massachusetts 02139 (US)
• **Depaulo, Raymond J., Jr.**
Baltimore, Massachusetts 21204-6526 (US)
• **McInnis, Melvin G.**
Timonium, Maryland 21093 (US)

(74) Representative: **Kirkham, Nicholas Andrew et al**
Graham Watt & Co.
St. Botolph's House
7-9 St. Botolph's Road
Sevenoaks Kent TN13 3AJ (GB)

(54) **BDNF polymorphism and association with bipolar disorder**

(57) Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and

pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

EP 1 233 075 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 02 25 1007
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	SAPOLSKY R J ET AL: "High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays" GENETIC ANALYSIS: BIOMOLECULAR ENGINEERING, ELSEVIER SCIENCE PUBLISHING, US, vol. 14, no. 5-6, February 1999 (1999-02), pages 187-192, XP004158703 ISSN: 1050-3862 * page 187, column 2, line 1 - line 9 * * page 188, column 1, line 7-20 *	10	C12Q1/68
Y	CRONIN M T ET AL: "APPLYING RAPID DNA MICROARRAY OPTIMIZATION CAPABILITY TO SNP SCREENING AND GENOTYPING" AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO., US, vol. 4, no. 65, October 1999 (1999-10), page A244 XP008006599 ISSN: 0002-9297 * abstract *	10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		14 November 2002	Hermann, P
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 02 25 1007

Claim(s) searched completely:
1-10

Claim(s) not searched:
11

Reason for the limitation of the search:

Claim 11 does not provide any indication as to any technical feature defining the compound to be protected (Article 84 EPC). Moreover, the description does not provide any such indication either. Hence the subject-matter of claim 11 can not be searched in a meaningful way.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 02 25 1007

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	GERHOLD D ET AL: "DNA chips: promising toys have become powerful tools." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND MAY 1999, vol. 24, no. 5, May 1999 (1999-05), pages 168-173, XP002216096 ISSN: 0968-0004 * page 169, column 2, paragraph 2 - column 3, paragraph 1 *	10	
A	KREBS M O ET AL: "ASSOCIATION STUDY OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISM IN SCHIZOPHRENIA" AMERICAN JOURNAL OF MEDICAL GENETICS, NEW YORK, NY, US, vol. 81, no. 6, 1998, page 520 XP000990211 * abstract *	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	EP 1 001 037 A (WHITEHEAD BIOMEDICAL INST) 17 May 2000 (2000-05-17) * the whole document *	1-9	
T	SKLAR P ET AL: "Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus." MOLECULAR PSYCHIATRY, vol. 7, no. 6, 2002, pages 579-593, XP002216091 2002 ISSN: 1359-4184 * tables 1,3 * * page 587, column 1, paragraph 2 * * page 587, column 2, paragraph 2 - page 591, column 1, paragraph 1 *	1-10	

	-/--		

EPO FORM 1503 03.02 (P04C10)



PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 02 25 1007

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,A	WO 01 11085 A (WHITEHEAD BIOMEDICAL INST ;LANDER ERIC S (US); SKLAR PAMELA (US)) 15 February 2001 (2001-02-15) * claims 1-5,14,17,23 *	1-10	
A	MCCARTHY J J ET AL: "THE USE OF SINGLE-NUCLEOTIDE POLYMORPHISM MAPS IN PHARMACOGENOMICS" NATURE BIOTECHNOLOGY, NATURE PUB. CO, NEW YORK, NY, US, vol. 18, May 2000 (2000-05), pages 505-508, XP000941628 ISSN: 1087-0156 * the whole document *		TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 25 1007

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-11-2002

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 1001037	A	17-05-2000	EP	1001037 A2	17-05-2000

WO 0111085	A	15-02-2001	AU	6899800 A	05-03-2001
			EP	1206578 A2	22-05-2002
			WO	0111085 A2	15-02-2001
			US	6458541 B1	01-10-2002

EPO FORM P0453

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82